ARIAD to Present At Wall Street Analyst Forum Institutional Investor Conference; Corporate Presentation to be Webcast Live.Business Editors/Heatlh & Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 5, 2001 ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the Company's chairman and chief executive officer, Harvey J. Berger, M.D., will present at the 40th institutional investor Institutional Investor A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions. conference sponsored by the Wall Street Analyst Forum on Wednesday, June 6, 2001 in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Dr. Berger will discuss the Company's business plans, lead product candidates and applications of its gene regulation technologies to genomics and proteomics. The presentation will be webcast live by the Wall Street Analyst Forum at 1:50 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT on June 6th. Investors can access the webcast at: www.corporate-ir.net/media_files/priv/21180/WSAF/schedule/060601.htm A replay of the presentation will be available by the end of the day on June 6th and will be archived for ten days. ARIAD is developing a pipeline of innovative pharmaceutical products based on small-molecule drugs and its proprietary gene regulation technology platforms. The Company effectively integrates functional genomics and proteomics, protein engineering, and structure-based drug design in its drug discovery process. ARIAD's lead product candidates - treatments for osteoporosis, cancer, anemia, and graft-vs-host disease, the major complication of bone marrow transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. - all work through small-molecule regulation of cellular processes. ARIAD's benchmark gene regulation technologies, ARGENT ar·gent n. 1. Heraldry The metal silver, represented by the color white. 2. Archaic Silver or something resembling it. (TM), RPD RPD Rapid RPD Radiation Protection Dosimetry RPD Rapid Product Development RPD Rochester Police Department RPD Recurrent Pattern Detection (Commtouch anti-spam engine) RPD Relative Percent Difference RPD Removable Partial Denture (TM), and RGE RGE Range (surveys) RGE Rochester Gas and Electric RGE Resume Generating Event RGE Real Good Edition (TM), have been licensed to hundreds of academic institutions worldwide for scientific research. Commercial licenses to these technologies also are available to pharmaceutical and biotechnology companies to accelerate their drug discovery efforts and for collaborative development of novel products. Additional information about ARIAD can be found on the web at www.ariad.com. Some of the matters discussed in this news release are forward-looking statements. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied in such statements. These risks include, but are not limited to, risks and uncertainties regarding the Company's preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , the Company's ability to conduct clinical trials of its product candidates and the results of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on the Company's collaborators and other factors. These risks are identified in ARIAD's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission. The Company does not intend to update any of the forward-looking statements after the date of this presentation to conform these statements to actual results or to changes in the Company's expectations, except as required by law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion